Jayson Dallas, M.D.
Dr. Jayson Dallas has been a member of our Board of Directors since 2020. Dr. Dallas has served as Chief Executive Officer of Rivus Pharmaceuticals since July 2023, having served as Executive Chair of the company since April 2021. He previously served as President and Chief Executive Officer of Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, from June 2018 until its acquisition by Sociétés des Produits Nestlé, S.A., in October 2020. Prior to joining Aimmune, he served as the first Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical, Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche in the United Kingdom from January 2013 to July 2015. Before joining Roche, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Earlier in his career, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas is a board member of Rivus Pharmaceuticals. He previously served on the board of Arena Pharmaceuticals until its acquisition by Pfizer in March 2022. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.